+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sulphonamides Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 110 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 5026019
UP TO OFF until Jun 30th 2023
The sulphonamides market is anticipated to record a CAGR of nearly 4.1% over the forecast period.

The COVID-19 pandemic had a substantial impact on the market due to supply chain disruptions and pandemic-related restrictions worldwide. However, initially, many antibiotics were used to treat COVID-19, which were widely prescribed and studied as the COVID-19 remedy. During the COVID-19 outbreak, antibiotics were used to improve public health and decrease the potential of other infectious exposures. An article published by Bioorganic & Medicinal Chemistry Letters in January 2021 stated that a novel class of cyclic sulfonamide derivatives acted as a promising new template for SARS-CoV-2 inhibitors using structural activity relationship optimization, viral inhibitory assays, cytotoxicity assays, and pharmacokinetic studies. Thus, the sulphonamides market is expected to grow due to an increasing number of studies on various sulfonamide derivatives used to treat COVID-19 infections.

Certain factors that are driving the market's growth include the increasing prevalence of chronic diseases worldwide and growing R&D activities in pharmaceutical companies. As per an article published by JEADV in March 2022, more than 94 million Europeans complain of uncomfortable skin sensations like itching, burning, or dryness. The most frequently reported conditions were fungal skin infections (8.9%), acne (5.4%), and atopic dermatitis or eczema (5.5%). Alopecia, acne, eczema, and rosacea were more common in women, whereas men were more likely to suffer from psoriasis and sexually transmitted infections (STIs). Similarly, there is a high prevalence of the diverse range of skin infections, gastrointestinal tract (GIT) infections, urinary tract infections, and respiratory tract infections globally. For instance, as per the report published by Verywell Health in November 2022, urinary tract infection (UTI) is an infection of the urinary system, which can affect the bladder (cystitis), urethra (urethritis), or kidneys (pyelonephritis), and 6 in 10 women in the United States experienced a UTI.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and less time-consuming. However, increasing side effects associated with the use of sulfa drugs and the availability of substitute drugs may hinder the market's growth over the forecast period.

Key Market Trends

Urinary Tract Infection is Expected to Witness Significant Growth During the Forecast Period

Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections. It is more common in women than men. UTI is one of the most frequent causes of morbidity and mortality, globally. The prevalence of uncomplicated UTIs is significantly higher compared to recurring, complicated UTIs.

As per the study report published by the European Journal of Medical Research in February 2022, urinary tract infections are highly prevalent in patients with type 2 diabetes. A number of research studies on aging participants showed that the prevalence of urinary tract infections in diabetic Iranian patients increased due to their growing age. Hence, the increasing prevalence of UTI due to the growing elderly population is expected to boost the demand for antimicrobials like sulphonamides and help in the market's growth over the forecast period.

With new research funding for infectious diseases, including UTIs, and the substantial availability of various sulfonamide drug formulations at a reasonable price, the prevalence of complicated UTIs is expected to increase in the future, owing to the rising drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe sulphonamides to treat UTI cases, which may also contribute to the growth of the market in the future.

North America is Expected to Register Significant Growth in the Market During the Forecast Period

North America is expected to have significant growth in the market due to growing R&D activities in medical sciences, availability of technologically advanced products, rising use of antibiotics, and the growing elderly population.

The rising incidence of tuberculosis in the region is the key factor driving the market's growth as sulphonamide is used as a potential medicine to treat drug-resistant tuberculosis. For instance, according to the CDC's NTSS, 7,860 tuberculosis cases were reported in 50 US states and the District of Columbia (DC) in 2021. The national incidence of reported tuberculosis cases (cases per 100,000 people) increased by 9.4% in 2021 (2.37) compared to the previous year. As per the same source, in 2021, some of the regions with the highest number of tuberculosis cases were California (1,750), Texas (991), Florida (499), Pennsylvania (166), Ohio (149), and Arizona (129). Thus, widespread tuberculosis in the region needs proper treatment measures, which may drive the demand for sulphonamides in the region.

In North America, the United States is expected to witness notable growth in the sulphonamide market during the forecast period due to the high prevalence and incidence of infectious diseases. According to the article by the CDC published in November 2021, the common cold affects millions of people in the United States each year. On average, adults have cold 2-3 times every year, with children being more at risk. Thus, due to the high burden of bacterial infectious diseases, the United States is expected to hold a major share of the sulphonamides market in North America.

Competitive Landscape

The sulphonamides market is fragmented and consists of several major players. Companies like AA Pharma Inc., Abbott Laboratories, Akorn Operating Company LLC, GSK PLC, Lexine Technochem Pvt. Ltd, Viatris Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd hold a substantial share in the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Growing R&D Activities in Pharmaceutical Companies
4.3 Market Restraints
4.3.1 Increasing Side Effects Associated with the Use of Sulfa Drugs
4.3.2 Availability of Substitute Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Topical
5.1.3 Other Routes of Administration
5.2 By Application
5.2.1 Skin Infections
5.2.2 Gastro Intestinal Tract (GIT) Infection
5.2.3 Urinary Tract Infection (UTI)
5.2.4 Respiratory Tract Infection (RTI)
5.2.5 Other Applications
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AA Pharma Inc.
6.1.2 Abbott Laboratories
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 GSK PLC
6.1.5 Lexine Technochem Pvt. Ltd
6.1.6 Viatris Inc.
6.1.7 Pfizer Inc.
6.1.8 Teva Pharmaceutical Industries Ltd
6.1.9 Amneal Pharmaceuticals LLC
6.1.10 Akorn Operating Company LLC

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AA Pharma Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Lexine Technochem Pvt. Ltd
  • Viatris Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amneal Pharmaceuticals LLC
  • Akorn Operating Company LLC